UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

PHASE3

Total Enrollment

177 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-11-30

Study Completion Date

2027-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

With this study - Total Therapy IIIB - researchers are extending the findings of Total Therapy III based what they have learned from the first two studies (Total Therapy I and II), with new research strategies designed to explore why chromosome abnormalities found in persons with multiple myeloma affect the outcome of drug therapy used in this disease."

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

UARK 2003-33, Total Therapy III

NCT00081939

Multiple Myeloma

COMPLETED PHASE2

Study of Multiple Myeloma Patients Relapsing or Progressing After Autologous Transplantation on Total Therapy 2

NCT00573391

Multiple Myeloma

TERMINATED PHASE3

UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy

NCT00083551

Multiple Myeloma

COMPLETED PHASE3

D.T. PACE Versus High Dose Melphalan and Autologous Transplant in Patients With Previously Treated Multiple Myeloma

NCT00083876

Multiple Myeloma

COMPLETED PHASE3

Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy

NCT00871013

Myeloma

ACTIVE_NOT_RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

It is well known that myeloma patients with chromosome abnormalities are at higher risk because their disease tends to be more aggressive and does not respond to treatment as well as patients without chromosome abnormalities. When researchers at the Myeloma Institute looked at the results of Total Therapy II, they found that although research subjects with chromosome abnormalities had better outcomes (how many responded, and how long they survived) than those treated with standard chemotherapy; still their outcomes did not improve significantly with Total Therapy II, when compared to Total Therapy I.

The research in this new study is designed to target this high-risk group of individuals with chromosomal abnormalities. However, it is hoped that both groups of research participants - those with and without chromosome abnormalities - will derive benefit from changes made in this new research study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Multiple Myeloma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

VDTPACE

Velcade, Dexamethasone, Thalidomide, Cisplatinin, Adriamycin, Cyclophosphamide and Etoposide

Group Type EXPERIMENTAL

Velcade

Intervention Type DRUG

Will be given in central venous catheter

Thalidomide

Intervention Type DRUG

Capsule taken by mouth

Dexamethasone

Intervention Type DRUG

A pill taken by mouth

Adriamycin

Intervention Type DRUG

Given into the vein (IV) by a continuous infusion through a central catheter

Cisplatin

Intervention Type DRUG

Given into the vein (IV) by a continuous infusion through a central catheter

Cyclophosphamide

Intervention Type DRUG

Given into the vein (IV) by a continuous infusion through a central catheter

Etoposide

Intervention Type DRUG

Given into the vein (IV) by a continuous infusion through a central catheter

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Velcade

Will be given in central venous catheter

Intervention Type DRUG

Thalidomide

Capsule taken by mouth

Intervention Type DRUG

Dexamethasone

A pill taken by mouth

Intervention Type DRUG

Adriamycin

Given into the vein (IV) by a continuous infusion through a central catheter

Intervention Type DRUG

Cisplatin

Given into the vein (IV) by a continuous infusion through a central catheter

Intervention Type DRUG

Cyclophosphamide

Given into the vein (IV) by a continuous infusion through a central catheter

Intervention Type DRUG

Etoposide

Given into the vein (IV) by a continuous infusion through a central catheter

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Bortezomib, PS-341 Thalomid Decadron, NSC-34521 Doxorubicin, NSC-123127 Cis-diamminedichloroplatinum [CDDP], Platinol, NSC-119875 Cytoxan, NSC-26271 VP-16), Vepesid®, Ethylidene-Lignan P., NSC-141540

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients must have newly diagnosed active MM requiring treatment. Patients with a previous history of smoldering myeloma will be eligible if there is evidence of progressive disease requiring chemotherapy.
* Protein criteria must be present (quantifiable serum M-component of IgG, IgA, IgD, or IgE; urinary kappa or lambda light chain; or serum free light chain (SFLC) levels in order to evaluate response. Non-secretory patients are eligible provided the patient has \> 20% plasmacytosis OR multiple (\>3) focal plasmacytomas or focal lesions on MRI OR diffuse hyperintense signal on STIR images in the absence of hematopoietic growth factors.
* Patients must have received no more than one cycle or one month of prior chemotherapy for this disease. Patients may have received prior radiotherapy provided approval has been obtained by the Principal Investigator.
* Patients must be \<75 years of age at the time of initial registration.
* Ejection fraction by ECHO or MUGA ≥ 40% performed within 60 days prior to registration.
* Patients must have adequate pulmonary function studies \> 50% of predicted on mechanical aspects (FEV1, FVC, etc) and diffusion capacity (DLCO) \> 50% of predicted, within 60 days of registration. If the patient is unable to complete pulmonary function tests due to MM related pain or condition, exception may be granted if the principal investigator documents that the patient is a candidate for high dose therapy.
* Patients must have a performance status of 0-2 based on SWOG criteria. Patients with a poor performance status (3-4), based solely on bone pain, will be eligible.
* All patients must be informed of the investigational nature of this study and must have signed an IRB-approved informed consent in accordance with institutional and federal guidelines.

Exclusion Criteria

* Platelet count \< 30 x 109/L, unless myeloma-related.
* 5.1.2.2 Grade \> 2 peripheral neuropathy.
* Hypersensitivity to bortezomib, boron, or mannitol.
* Uncontrolled diabetes.
* Recent (\< 6 months) myocardial infarction, unstable angina, difficult to control congestive heart failure, uncontrolled hypertension, or difficult to control cardiac arrhythmias.
* Evidence of chronic obstructive or chronic restrictive pulmonary disease.
* Patients must not have light chain deposition disease or creatinine \> 3 mg/dl
* Patients must not have prior malignancy, except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the patient has not received treatment for one year prior to enrollment. Other cancers will only be acceptable if the patient's life expectancy exceeds five years.
* Patients must not have significant co-morbid medical conditions or uncontrolled life threatening infection.
* Pregnant or nursing women. Women of child-bearing potential must have a negative pregnancy test documented within one week of registration. Women and men of reproductive potential may not participate unless they have agreed to use an effective contraceptive method.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No